Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.49 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4958840 | 0.83 | MEN1 (0.68) | GAASMN1; SMN2MEN1KMT2AKDM1A | |
| SCHEMBL4958523 | 0.83 | GAA (0.68) | GAASMN1; SMN2MEN1KMT2ACARM1 | |
| SCHEMBL3932594 | 0.82 | GAA (0.70) | GAASMN1; SMN2MEN1KMT2AKDM1A | |
| SCHEMBL6254840 | 0.77 | CHRNA7 (0.46) | CHRNA7 | |
| SCHEMBL3695388 | 0.76 | MEN1 (0.54) | GAASMN1; SMN2MEN1KMT2AKDM1A | |
| SCHEMBL3695387 | 0.76 | MEN1 (0.54) | GAASMN1; SMN2MEN1KMT2AKDM1A | |
| SCHEMBL8252682 | 0.74 | GAA (0.68) | GAASMN1; SMN2MEN1KMT2AKDM1A | |
| SCHEMBL13917294 | 0.74 | CARM1 (0.63) | MEN1KMT2AKDM1ACARM1PRMT6 | |
| SCHEMBL12615044 | 0.74 | CHRNA7 (0.58) | GAACHRNA7 | |
| SCHEMBL13644190 | 0.73 | KDM1A (0.57) | GAAKDM1ACARM1PRMT6PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083355-A1 | COMPOUNDS WHICH HAVE A PROTECTIVE ACTIVITY WITH RESPECT TO THE ACTION OF TOXINS AND OF VIRUSES WITH AN INTRACELLULAR MODE OF ACTION | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2016-03-24 | — | — | US | claimed |
| US-20120283249-A1 | Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2012-11-08 | — | — | US | claimed |
| EP-2145873-A1 | New compounds with activity that protects against the action of toxins and viruses in intracellular action mode | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-01-20 | — | — | EP | claimed |
| EP-3239131-A1 | NEW COMPOUNDS WITH ACTIVITY THAT PROTECTS AGAINST THE ACTION OF TOXINS AND VIRUSES IN INTRACELLULAR ACTION MODE | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2017-11-01 | — | — | EP | disclosed |
| EP-3239131-A1 | NEW COMPOUNDS WITH ACTIVITY THAT PROTECTS AGAINST THE ACTION OF TOXINS AND VIRUSES IN INTRACELLULAR ACTION MODE | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2017-11-01 | — | — | EP | disclosed |
| US-20170233386-A1 | Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-08-17 | — | — | US | disclosed |
| US-20170233386-A1 | Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-08-17 | — | — | US | disclosed |
| US-20170233386-A1 | Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-08-17 | — | — | US | disclosed |
| US-20160083355-A1 | COMPOUNDS WHICH HAVE A PROTECTIVE ACTIVITY WITH RESPECT TO THE ACTION OF TOXINS AND OF VIRUSES WITH AN INTRACELLULAR MODE OF ACTION | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2016-03-24 | — | — | US | disclosed |
| US-20160083355-A1 | COMPOUNDS WHICH HAVE A PROTECTIVE ACTIVITY WITH RESPECT TO THE ACTION OF TOXINS AND OF VIRUSES WITH AN INTRACELLULAR MODE OF ACTION | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2016-03-24 | — | — | US | disclosed |
| US-20160083355-A1 | COMPOUNDS WHICH HAVE A PROTECTIVE ACTIVITY WITH RESPECT TO THE ACTION OF TOXINS AND OF VIRUSES WITH AN INTRACELLULAR MODE OF ACTION | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2016-03-24 | — | — | US | disclosed |
| US-20120283249-A1 | Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2012-11-08 | — | — | US | disclosed |
| US-20120283249-A1 | Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2012-11-08 | — | — | US | disclosed |
| EP-2145873-A1 | New compounds with activity that protects against the action of toxins and viruses in intracellular action mode | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283249-A1 | Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action | HAVCR2, MAVS, ANTXR2 | GAA 239/4885SMN1; SMN2 3101/4885MEN1 3020/4885 |
| US-20160083355-A1 | COMPOUNDS WHICH HAVE A PROTECTIVE ACTIVITY WITH RESPECT TO THE ACTION OF TOXINS AND OF VIRUSES WITH AN INTRACELLULAR MODE OF ACTION | HAVCR2, MAVS, ANTXR2 | GAA 189/4885SMN1; SMN2 3088/4885MEN1 2389/4885 |
| US-20170233386-A1 | Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action | HAVCR2, MAVS, ANTXR2 | GAA 189/4885SMN1; SMN2 3088/4885MEN1 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.